Sara Sampietro/LinkedIn
Nov 26, 2025, 10:32
Sara Sampietro Introduces The New HemosIL Chromogenic Factor IX
Sara Sampietro, Product Manager – EEMEA at Werfen, shared on LinkedIn:
”Last week in Nyborg, Denmark, I had the privilege to discuss the role of the laboratory in the management of patients with Hemophilia and introduce our latest release: the NEW HemosIL Chromogenic Factor IX.
A big thanks to our partner ILS and to everyone who joined the conversation and contributed to driving progress in Hemostasis care.
Together, we can continue to make a difference!”
Stay updated with Hemostasis Today.
-
Sep 21, 2026, 20:56George Touma: ApoB Should Be Central to All Lipid Guidlines
-
Sep 21, 2026, 20:55Christopher Robinson: Obstetric Risks Are Seen at the Extremes of Birthweight
-
Sep 21, 2026, 20:54Emicizumab for Refractory GI Bleeding in Myeloma-Associated Acquired VWD – JTH
-
Sep 21, 2026, 20:52Ross Baker: ASH 2026 Guidelines on Iron Deficiency in HMB and Bleeding Disorders
-
Sep 21, 2026, 20:50Rainer Kaiser: Genes and Signalling Pathways Implicated in Procoagulant Platelet Generation
-
Sep 21, 2026, 20:49Natalia Dovlatova: Celebrating Stan Heptinstall and His Legacy in Platelet Science
-
Sep 21, 2026, 20:48Norm Roulet: The Interaction of Pb and SARS-CoV-2 and Its Impact on the Cardiovascular System
-
Sep 21, 2026, 20:45Felix Scholkmann: The Spleen Plays a Key Role in Regulating Platelet Activity
-
Sep 21, 2026, 20:43Claire Pomeroy: Celebrating the 2026 Lasker Awards and Why Medical Research Matters